Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1550841 | 1.00 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL1358814 | 0.78 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL1358812 | 0.78 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL2286812 | 0.72 | DPP4 (0.36) | SMN1; SMN2 | |
| SCHEMBL1550843 | 0.72 | DPP4 (0.36) | SMN1; SMN2 | |
| SCHEMBL2285251 | 0.72 | DPP4 (0.36) | SMN1; SMN2 | |
| SCHEMBL12549405 | 0.69 | JAK1 (0.40) | SMN1; SMN2 | |
| SCHEMBL12548977 | 0.69 | JAK1 (0.40) | SMN1; SMN2 | |
| SCHEMBL12548978 | 0.68 | ALDH1A1 (0.41) | SMN1; SMN2 | |
| SCHEMBL12548504 | 0.68 | ALDH1A1 (0.41) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998949-B2 | Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-16 | — | — | US | disclosed |
| US-20100022505-A1 | BICYCLIC HETEROCYCLES, DRUGS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR PRODUCTION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-28 | — | — | US | disclosed |
| EP-2118075-A1 | BICYCLIC HETEROCYCLES, DRUGS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR PRODUCTION THEREOF | Boehringer Ingelheim International GmbH (DE) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008095847-A1 | BICYCLIC HETEROCYCLES, DRUGS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR PRODUCTION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022505-A1 | BICYCLIC HETEROCYCLES, DRUGS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR PRODUCTION THEREOF | RET, CYP11B2, CHUK | SMN1; SMN2 4691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.